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Abstract
Background: Traumatic brain injury (TBI) patients in military settings can be exposed to prolonged periods of
hypobaria (HB) during aeromedical evacuation. Hypobaric exposure, even with supplemental oxygen to prevent
hypoxia, worsens outcome after experimental TBI, in part by increasing neuroinflammation. Cell cycle activation
(CCA) after TBI has been implicated as a mechanism contributing to both post-traumatic cell death and
neuroinflammation. Here, we examined whether hypobaric exposure in rats subjected to TBI increases CCA and
microglial activation in the brain, as compared to TBI alone, and to evaluate the ability of a cyclin-dependent
kinase (CDK) inhibitor (CR8) to reduce such changes and improve behavioral outcomes.
Methods: Adult male Sprague Dawley rats were subjected to fluid percussion-induced injury, and HB exposure
was performed at 6 h after TBI. Western blot and immunohistochemistry (IHC) were used to assess cell cycle-related
protein expression and inflammation at 1 and 30 days after injury. CR8 was administered intraperitoneally at 3 h
post-injury; chronic functional recovery and histological changes were assessed.
Results: Post-traumatic hypobaric exposure increased upregulation of cell cycle-related proteins (cyclin D1,
proliferating cell nuclear antigen, and CDK4) and microglial/macrophage activation in the ipsilateral cortex at
day 1 post-injury as compared to TBI alone. Increased immunoreactivity of cell cycle proteins, as well as numbers of
Iba-1+ and GFAP+ cells in both the ipsilateral cortex and hippocampus were found at day 30 post-injury. TBI/HB
significantly increased the numbers of NADPH oxidase 2 (gp91phox) enzyme-expressing cells that were co-localized
with Iba-1+. Each of these changes was significantly reduced by the administration of CR8. Unbiased stereological
assessment showed significantly decreased numbers of microglia displaying the highly activated phenotype in the
ipsilateral cortex of TBI/HB/CR8 rats compared with TBI/HB/Veh rats. Moreover, treatment with this CDK inhibitor also
significantly improved spatial and retention memory and reduced lesion volume and hippocampal neuronal cell loss.
Conclusions: HB exposure following TBI increases CCA, neuroinflammation, and associated neuronal cell loss. These
changes and post-traumatic cognitive deficits are reduced by CDK inhibition; such drugs may therefore serve to
protect TBI patients requiring aeromedical evacuation.
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Background
Traumatic brain injury (TBI) is a major cause of morbidity
and mortality in civilian populations [1] and has been a
serious concern for US military forces, where the number
of cases has nearly tripled over the last decade [2]. TBI
casualties are moved from the battlefield to the appropri-
ate level of care through the military aeromedical evacu-
ation (AE) system [3]. During transport, patients can be
exposed to long periods of hypobaria (HB), as military
flights are often pressurized only to 8000 ft, substantially
different from commercial air travel [3, 4]. It has been re-
cently shown in a rat TBI model that hypobaria during
simulated AE worsens cognitive and pathological out-
comes [5]; this report and an earlier one using a mouse
TBI model also suggest that hypobaria can increase post-
traumatic inflammatory responses [6].
TBI-related neuropathology reflects both direct mech-
anical damage (primary injury) and delayed induced mo-
lecular and cellular cascades (secondary injury)—leading
to neuronal cell death, axonal disruption, demyelination,
astrogliosis, and inflammation [7]. Cell cycle activation
(CCA) occurs after TBI in both neurons and glial cells
and contributes to secondary injury [8–10]. In post-
mitotic cells such as neurons, CCA contributes to pro-
grammed cell death. In glia, CCA induces astrocyte and
microglial proliferation/reactivation, leading to astroglial
scar formation, release of pro-inflammatory cytokines
and reactive oxygen species (ROS), and ultimately
neuronal degeneration [8–10]. Administration of cell
cycle inhibitors after TBI increases neuronal survival
and reduces both microglial and astroglial activation; the
latter includes multiple studies utilizing the rat LFP
injury model [11–15].
TBI-induced neuroinflammation appears to play a pivotal
role in secondary injury severity and progression. Although
the neuroinflammatory response to injury may have either
beneficial or detrimental actions [16], both pre-clinical and
clinical studies show that chronic microglial activation after
TBI contributes to both progressive neurodegeneration and
related neurological deficits [17–19]. As sustained post-
traumatic CCA appears to contribute to chronic neuroin-
flammation, this study was designed to evaluate whether HB
following TBI increases both CCA and related neuroinflam-
mation and whether CCA inhibition can limit these harmful




Male Sprague Dawley rats (Harlan Labs, Frederick, MD)
weighing 325 g (±25 g) were utilized for this study. Animals
were fed a standard laboratory diet with food and water ad
libitum. All procedures and experiments were carried out in
accordance with protocols approved by the Animal Care
and Use Committee at the University of Maryland and the
United States Air Force.
Micro-fluid percussion and hypobaric animal experiments
Rats were anesthetized with isoflurane (4% induction, 2%
maintenance), and a 5-mm craniotomy was made over the
left parietal cortex midway between the lambda and
bregma as previously described [5, 20]. Using our custom
micro-fluid percussion (FP) device, a 1.5–1.9-atmosphere
(atm) pressure was used to produce a mild injury with
regard to neurologic and histologic deficits [20]. Sham ani-
mals underwent the same procedures without injury.
Hypobaria was induced using a steel cylindrical chamber
with interior dimensions of 46 cm wide and 112 cm long
equipped with internal temperature, oxygen, carbon diox-
ide, and pressure gauges and connected to a vacuum
pump. Animals were placed into the chamber in their
home cages with access to water and food to reduce stress
from acclimation to the HB chamber. Multiple animals in
various groups were randomly exposed simultaneously.
The chamber was de-pressurized over 30 min to reach
568 mmHg (=8000 ft. altitude)—approximating the cabin
pressure during military AE with cruising altitudes of
30,000–40,000 ft. To account for the mean oxygen satur-
ation decrease of 5.5% experienced at this pressure, 28%
O2 was continuously delivered to the chamber to maintain
pO2 at sea level despite the drop in atmospheric pressure.
Chamber gases were continuously monitored to validate
concentration of O2 delivered, as well as to verify that
CO2 was not accumulating in the chamber. At 5.5 h of
“flight,” the chamber was re-pressurized over 30 min to
1 atm (765 mmHg), and the animals were then removed.
Interior chamber temperature was monitored continuously
and maintained at 22 ± 2 °C.
Experimental procedure
An inhibitor of cell cycle activation—(2-(R)-(1-ethyl-2-
hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropyl-
purine trihydrochloride (CR8, Tocris Bioscience,
Minneapolis, MN), was evaluated for its effects on cellu-
lar inflammatory reactions (microglial and astrocyte acti-
vation) as well as on histologic and neurologic outcome
after TBI. For tissue collection experiments, male rats
were randomized to one of four groups: sham injury, TBI
alone, TBI +HB + vehicle (Veh), and TBI +HB + CR8
(Fig. 1). For behavioral analysis and stereology experi-
ments, male rats were randomized to one of three groups:
sham injury, TBI +HB +Veh, and TBI +HB + CR8 (Fig. 1).
We have previously reported a TBI-alone group for behav-
ioral analysis [5]. Animals in the treatment groups re-
ceived a dose of CR8 (5 mg/kg in saline, IP) or an equal
volume of vehicle (saline) 3 h following the induction of a
TBI. Six hours after the induction of TBI (1.5–1.9 atm),
the animals were exposed to HB for 6 h at 0.75 atm. This
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dose and timing of administration was based on previous
studies using this compound in experimental animal
models of TBI—which have shown neuroprotection by
limiting microglial activation, astrocytosis, and neuronal
loss [5, 15]. Behavioral tests were conducted over 30 days
post-HB. This experimental timeline was chosen to be
consistent and comparable to established procedures for
accurate assessment of behavioral and histological
outcomes following TBI [5, 15]. All behavioral tests were
conducted by an experimenter blinded to the experimen-
tal groups. Behavioral testing included Morris water maze
tests for learning and memory (post-HB days 14–18),
novel object recognition test for retention memory (post-
HB day 21), and the forced swim test (post-HB day 26) for
depressive-like behaviors. Brains were collected at 24 h
post-injury or on post-HB day 30 for pathologic or immu-
nohistochemical analysis. The number of rats in each
group or subgroup is indicated in Table 1.
Tissue collection and western blot
At 24 h post-injury, rats were anesthetized with sodium
pentobarbital (100 mg/kg, IP). A blunt 21-gauge needle
connected to a peristaltic pump (Harvard Apparatus,
Holliston, MA) primed with 0.9% sodium chloride
(saline) was pierced through the left lateral ventricle and
inserted diagonally into the ascending aorta. An incision
was then made in the right atrium to allow the fluid to
flow through. The brain was perfused with saline at a
rate of 50 ml/min for 10 min before being removed. A
5-mm area surrounding the lesion epicenter on the ipsi-
lateral cortex was rapidly dissected placed in a 1-ml
microcentrifuge tube and flash frozen with liquid nitro-
gen. Frozen tissue samples were stored at −80 °C prior
to analysis.
For all immunoblot samples, the cortical tissue was
homogenized in radioimmunoprecipitation assay (RIPA)
buffer and centrifuged at 15,000 rpm for 15 min at 4 °C
to isolate proteins, and the protein concentration was
determined using the Pierce BCA Protein Assay kit
(Thermo Scientific, Rockford, IL). Twenty-five microgram
of protein was run on sodium dodecyl sulfate (SDS) poly-
acrylamide gel electrophoresis and transferred onto nitro-
cellulose membrane (n = 6–10/group). The blots were
probed with antibodies against cyclin-dependent kinase
(CDK)4 (1:1000, Santa Cruz Biotechnology, Inc., Santa
Cruz, CA); cyclin D1 (1:500, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA); proliferating cell nuclear antigen
(PCNA; 1:500, Santa Cruz Biotechnology); and ionized
calcium-binding adapter molecule 1 (Iba-1; 1:1000, Wako
Chemicals, Richmond, VA), and GAPDH (1:2000; Sigma-
Aldrich, St. Louis, MO) was used as an endogenous
control. Immune complexes were detected with the ap-
propriate horseradish peroxidase (HRP)-conjugated
secondary antibodies (KPL, Inc., Gaithersburg, MD)
and visualized using SuperSignal West Dura Extended
Duration Substrate (Thermo Scientific, Rockford, IL).
Chemiluminescence was captured on a Kodak Image
Station 4000R station (Carestream Health, Rochester, NY),
and protein bands were quantified by densitometric analysis
using Carestream Molecular Imaging Software. The data
presented reflect the intensity of the target protein band
compared to the control and were normalized based on the
intensity of the endogenous control for each sample.
Functional assessment
Morris water maze
Spatial learning and memory were assessed using the ac-
quisition paradigm of the Morris water maze (MWM)
test as previously described [15]. A circular pool (1.5 m
in diameter) was divided into four quadrants using
computer-based AnyMaze video tracking system (Stoelt-
ing Co., Wood Dale, IL). Each rat was subjected to four
trials to locate the hidden platform every day from post-
HB days 14 to 17 (acquisition phase). Latency (seconds)
to locate the hidden platform was measured, with a 90-s
limit per trial, and swimming velocities assessed. Water
maze search strategy analysis was also performed as pre-
viously described [15]. Reference memory was assessed
by a probe trial carried out on post-HB day 18. A visual












Fig. 1 Experimental timeline for evaluating CR8 treatment on simulated
AE-induced cell cycle activation and inflammatory responses following TBI
Table 1 Definition of the groups
Groups/rats # Functional
assessment








Sham 16 Behavioral tests, IHC
TBI 6 IHC
TBI/Veh/HB 14 Behavioral tests, IHC, lesion
volume, stereology
TBI/CR8/HB 15 Behavioral tests, IHC, lesion
volume, stereology
TBI traumatic brain injury, WB western blot, HB hypobaria, Veh vehicle,
IHC immunohistochemistry
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Novel object recognition
Nonspatial retention and recognition memory was
assessed by the novel object recognition test as previ-
ously described [5, 15]. On post-HB day 20, animals
were placed into the open field and allowed to explore
for 10 min each without any of the objects present for
habituation and familiarization. On the testing day
(post-HB day 21), two trials of 5 min each were per-
formed. The first trial (training phase) involved placing
identical square-shaped “old objects” in both zones of
the open field. The second trial (testing phase) involved
placing one square-shaped “old object” and one triangular-
shaped “novel object” in the respective zones of the open
field. The time that was spent exploring each object during
both trials was recorded. In addition, time spent in the
novel object and old object zones was analyzed and com-
pared between groups separately. The cognitive outcomes
were calculated as the “discrimination index” (D.I.) for the
second trial using the following formula: % D.I. = (time
spent exploring novel object / (total time spent exploring
both objects)) × 100.
Forced swim test
The forced swim test was used to examine depressive-
like behaviors [5, 15]. On post-HB day 26, rats were
individually forced to swim inside a vertical plastic con-
tainer (height 60 cm; diameter 25 cm) containing 30 cm
of water for a time period of 6 min. The total duration
of immobility (passive floating, slightly hunched, upright
position, the head just above the surface) vs. struggle
(diving, jumping, strongly moving all four limbs, scratching
the walls) was recorded.
Tissue processing, immunohistochemistry, image
acquisition, and quantification
At 30 days after injury, rats were anesthetized and in-
tracardially perfused with 200 ml of saline followed
by 300 ml of 4% paraformaldehyde. The dissected
brains were post-fixed for overnight and cryopro-
tected through a sucrose gradient. The coronal
sections were cut, serially collected (3 × 60 μm
followed by 3 × 20 μm sections) throughout the brain
and mounted onto glass slides for histology and
immunohistochemistry.
Standard fluorescent immunohistochemistry on ser-
ial, 20-μm-thick sections was performed as described
previously [21]. The following primary antibodies were
used: rabbit anti-CDK4 (1:500, Santa Cruz Biotechnology);
mouse anti-cyclin D1 (1:500, Neomarker); rabbit anti-
PCNA (1:500, Santa Cruz Biotechnology); rabbit or
mouse anti-GFAP (1:1000, Chemicon); rabbit anti-Iba-1
(1:1000, Wako Chemicals); mouse anti-gp91phox (1:500;
BD Transduction Laboratories, Franklin Lakes, NJ);
and galectin 3 (1:500, Santa Cruz Biotechnology).
Fluorescent-conjugated secondary antibodies (1:1000,
Alexa 488-conjugated goat anti-mouse or rabbit, Alexa
Fluor 546 goat anti-mouse, Alexa Fluor 633 goat anti-
mouse, Molecular Probes) were incubated with tissue sec-
tions for 1 h at room temperature. Counterstaining was
performed with 4′,6-diamidino-2-phenylindole (DAPI)
(1 μg/ml; Sigma-Aldrich). All immunohistological staining
experiments were carried out with appropriate positive
control tissue as well as primary/secondary-only negative
controls.
For quantitative image analysis, images were acquired
using a fluorescent Nikon Ti-E inverted microscope, at
×20 (CFI Plan APO VC 20× NA 0.75 WD 1 mm) magni-
fication. Exposure times were kept constant for all sec-
tions in each experiment. Background for all images was
subtracted using Elements. All images were quantified
using Elements: nuclei were identified using Spot Detec-
tion algorithm based on DAPI staining; cells positive for
any of the immunofluorescence markers were identified
using Detect Regional Maxima or Detect Peaks algo-
rithms, followed by global thresholding. The intensity of
cyclin D1, PCNA, and CDK4 was normalized to the total
area imaged. The number of positive cells was normal-
ized to the total number of cells based on DAPI staining.
All quantifications were performed in the ipsilateral cor-
tex and hippocampus. For each experiment, data from
all images from one region in each animal were sum-
mated and used for statistical analysis [22, 23]. At least
1000–2000 cells were quantified for each rat per area
per experiment.
Stereological quantification of microglial phenotypes in
the ipsilateral cortex
Every fourth 60-μm brain section was immunostained
for Iba-1 and DAB and analyzed using a Leica DM4000B
microscope (Leica Micro-systems Inc., Buffalo Grove, IL,
USA). The number of cortical microglia in either acti-
vated (hypertrophic and bushy) or resting (ramified)
morphologic phenotypes were counted using the optical
fractionator method with the Stereo Investigator soft-
ware (MBF Biosciences) as described previously [5, 15].
Microglial phenotypic classification was based on the
length and thickness of the projections, the number of
branches, and the size of the cell body, as previously
described [5]. The sampling region was between −2.04
and −4.56 mm from the bregma in the ipsilateral cor-
tex with a dorsal depth of 2.0 mm from the surface.
The volume of the region of interest was measured
using the Cavalieri estimator method. The estimated
number of microglia in each phenotypic class was
divided by the volume of the region of interest to ob-
tain cellular density expressed in counts per cubic
millimeters (mm3).
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Lesion volume and neuronal survival in the hippocampal
subregions
Sections were stained with cresyl violet (FD Neuro-
Technologies, Baltimore, MD), dehydrated, and mounted
for analysis. Lesion volume was quantified based on the
Cavalieri method of unbiased stereology using Stereologer
2000 program software (Systems Planning and Analysis,
Alexandria, VA). The lesion volume was quantified by out-
lining the missing tissue on the injured hemisphere using
the Cavalieri estimator with a grid spacing of 0.1 mm.
Every fourth 60-μm section between −2.04 and −4.56 mm
from the bregma was analyzed beginning from a random
start point.
The total number of surviving neurons in the cornus
ammonis (CA)1, CA2, CA3, and dentate gyrus (DG)
subregions of the hippocampus was assessed using the
optical fractionator method [5, 15]. Every fourth 60-μm
section between −2.04 and −4.56 mm from the bregma
was analyzed, beginning from a random start point. The
volume of each hippocampal subfield was measured
using the Cavalieri estimator method. The estimated
number of surviving neurons in each field was divided
by the volume of the region of interest to obtain the
neuronal cellular density, expressed as counts/mm3.
Statistical analysis
Quantitative data were expressed as mean ± standard
error of the mean (SEM). Analysis of histological data
was conducted using a one-way ANOVA followed by the
Student-Newman-Keuls post hoc test. Functional data
(latency to find the platform in seconds) for the acquisi-
tion phase of the MWM were analyzed by repeated
measure (trial over time) two-way ANOVA (TBI +
Veh + HB vs. TBI + CR8 + HB) to determine the inter-
actions of post-injury days and groups, followed by
post hoc adjustments using the Student-Newman-Keuls
test. As we are only interested in whether CR8 treatment
improves outcomes over TBI +HB with vehicle treatment,
further analysis of behavioral outcomes was conducted
using a one-tailed unpaired Student’s t test to determine
the differences between groups within each trial day.
The comparison of search strategies during the final
day of the trials of the MWM acquisition phase was an-
alyzed using a chi-square test. As we are only interested
in whether CR8 treatment improves outcomes over
TBI + HB with vehicle treatment, all other analyses
(MWM probe, novel object, forced swim, stereological
assessments, lesion volume) were conducted using a
one-tailed unpaired Student’s t test (TBI + Veh + HB vs.
TBI + CR8 +HB). All tests were performed using either
SigmaPlot 12 (Systat Software, San Jose, CA) or GraphPad
Prism program; version 4.0 (GraphPad Software; San
Diego, CA). A p value of less than 0.05 was considered
statistically significant.
Results
Post-traumatic hypobaria exposure increases CCA as
compared to TBI alone
To evaluate the effect of HB on cell cycle activation, we
first examined cell cycle pathway changes in the ipsilate-
ral cortex at day 1 after TBI. Western blotting was
performed for the markers of cell cycle-related proteins
cyclin D1, PCNA, and CDK4 (Fig. 2). At 24 h post-
injury, a significant increase in the protein expression of
these markers was observed in the injured/no-HB ex-
posure group (n = 9) in comparison to the sham injury
group (n = 7, p < 0.001, TBI/no-HB vs. sham injury). HB
exposure following TBI (n = 10) significantly further in-
creased the protein expression of cyclin D1, PCNA, and
CDK4 in comparison to the TBI/no-HB exposure group (p
< 0.001 for CDK4, p < 0.05 for cyclin D1, TBI +HB vs. TBI/
no-HB). In contrast, cell cycle inhibition by administration
of CR8 (n = 7) limited the TBI +HB-induced increase in
the expression of these cell cycle proteins at 1 day post-
injury (p < 0.05 for cyclin D1 and PCNA, p < 0.001 for
CDK4, TBI +Veh +HB vs. TBI + CR8 +HB).
We also examined immunoreactivity of cyclin D1,
PCNA, and CDK4 in the ipsilateral cortex and hippocam-
pus from sham (n = 4), TBI alone (n = 6), TBI + Veh +HB
(n = 6), and TBI + CR8 +HB (n = 6) rats at 30 days post-
injury. Quantification of pixel intensity for these markers
showed significant increases in the TBI + Veh +HB group
in contrast to the TBI-alone tissue (Figs. 3, 4, and 5).
Cyclin D1 was predominantly expressed by GFAP+ astro-
cytes (Fig. 3d). Most of the PCNA+ cells in the injured
cortex were co-labeled with galectin 3-expressing micro-
glia/macrophages (Fig. 4d). Some of the CDK4+ cells dis-
played neuronal morphology and co-labeled with NeuN
(Fig. 5a, d). In addition, CDK4 was also expressed by as-
trocytes (data not shown). The post-traumatic upregula-
tion of these proteins was attenuated by CR8 treatment.
Cell cycle inhibition reduces microglial activation and
astrogliosis induced by hypobaria exposure following TBI
To examine whether HB-induced activation of microglia
and astrocytes were attenuated by inhibiting CCA, rats
were treated with CR8 or saline by ip injection at 3 h post
injury and the ipsilateral cerebral cortical tissue was col-
lected at 24 h after TBI. Quantitative analysis of western
blots showed that Iba-1 expression in TBI (n = 9) or TBI
+ Veh +HB (n = 10) groups increased by approximately
1.5- or 2.1-fold, respectively, as compared to sham-injured
animals (n = 7, Fig. 6a, b). Notably, CR8 treatment (n = 7)
significantly attenuated (TBI + Veh +HB)-induced in-
crease of Iba-1 expression. Moreover, immunohistochemi-
cal analysis demonstrated that TBI + Veh +HB (n = 6), in
contrast to TBI-alone tissue (n = 6), caused a 1.4-fold of
the total number of Iba-1+ microglia/macrophages at
30 days post-injury in both the ipsilateral cortex and
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hippocampus (Fig. 6c–e). CR8-treated rats (n = 6) showed
significantly reduced total numbers of Iba-1+ cells.
It is well known the TBI significantly increases micro-
glial activation [7–15]. In our previous study, we have
shown that TBI + HB further increases activated micro-
glia at 30 days in comparison to TBI alone [5]. In order
to examine if CR8 treatment reduced the neuroinflam-
matory response associated with TBI + HB, stereological
quantifications of resting and activated microglia cell
numbers in the injured cortex were evaluated at 30 days
post-HB. CR8 treatment (n = 6, Fig. 7) significantly
reduced the total number of microglia and number of
activated microglia in comparison to the TBI + HB group
(p < 0.01, TBI + CR8 +HB vs. TBI + Veh + HB).
In addition, we evaluated the effect of HB on the expres-
sion of NADPH oxidase membrane component gp91phox
after TBI. Immunohistochemistry at 30 days post-injury
demonstrated that TBI + Veh +HB (n = 6) significantly in-
creased the total numbers of gp91phox-positive cells in
contrast to TBI-alone tissue (n = 6, Fig. 8a–c). Moreover,
double-labeling immunohistochemistry revealed that large
numbers of gp91phox-positive cells in the injured coronal
sections were colabeled with Iba-1 (Fig. 8d). Notably, there
were fewer gp91phox-positive cells in the CR8-treated
TBI + HB samples (n = 6), and Iba-1 expression was also
reduced in these cells.
Quantitative immunofluorescence image analysis also
showed significant increases in the total numbers of
GFAP+ astrocytes in the TBI + Veh +HB group (n = 6) in
contrast to the TBI-alone tissue (n = 6, P < 0.01; Fig. 9).
Notably, there were significant reductions in the posi-
tively stained cells in both the ipsilateral cortex and
hippocampus in CR8-treated animals (n = 6, P < 0.01).
Cell cycle inhibition by CR8 improves functional
outcomes following TBI + HB
The MWM was used to evaluate if CR8 treatment atten-
uates deficits in spatial learning caused by HB exposure
following TBI (Fig. 10a). The factors of “post-injury
days” (F(3126) = 102.803; p < 0.001) and “groups”
(F(2126) = 12.576; p < 0.001) were found to be signifi-
cant. The interaction of “post-injury days × groups”
(F(6126) = 7.730; p < 0.01; repeated measures two-way
ANOVA) was significant. Further analysis of differences
between groups for each trial day was conducted using a
one-tailed unpaired Student’s t test. The TBI + CR8 + HB
group showed significant improvement in the spatial
learning deficits in comparison to the TBI + Veh + HB
Fig. 2 Hypobaria exposure increases markers of cell cycle activation at 24 h after TBI. a Representative immunoblots for cell cycle-related proteins (cyclin D1,
PCNA, and CDK4) and the loading control (GAPDH). b–d Expression levels of cell cycle proteins were normalized by GAPDH, as estimated by optical density
measurements, and expressed as a percentage of sham tissue. At 24 h post-injury, a significant increase in the protein expression of cyclin D1, PCNA, and
CDK4 was observed in the TBI/no-HB exposure group in comparison to the sham injury group. HB exposure following TBI significantly increased the protein
expression of all three markers in comparison to the TBI-alone group. A significant decrease in the protein expression of all three markers was observed in the
CR8 treatment group in comparison to the TBI/Veh/HB group. N= 7 (sham), 9 (TBI), 10 (TBI/Veh/HB), 7 (TBI/CR8/HB). *p< 0.05, ***p<0.001, TBI vs. sham injury;
#p< 0.05, ###p< 0.001, TBI/Veh/HB vs. TBI/no-HB; $p<0.05, $$$p< 0.001, TBI/CR8/HB vs. TBI/Veh/HB
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group on trial day 4 (Fig. 10a: p < 0.05). The mean es-
cape latency on the last day of training was 30.2 ± 3.9 s
for the sham-injured group, 68.6 ± 6.7 for the Veh +HB
group, and 51.0 ± 6.7 for the CR8-treated group.
The swimming patterns during all trials on the fourth
day of the acquisition phase were analyzed to assess the
search strategies utilized by the animals to locate the
hidden platform (Fig. 10b). A chi-square analysis was
used to compare strategies between groups (p < 0.001;
χ2 = 57.79, df = 4). HB-exposed animals were less effi-
cient in their search strategy while attempting to locate
the hidden platform with only 32% of the day 4 trials
reflecting a spatial strategy. CR8-treated animals utilized
a spatial search strategy on day 4 in a higher percentage
of trials 61% than untreated injured animals. Spatial
memory was assessed using the MWM probe trial on
day 18 after HB by examining the number of entries into
the target quadrant (Fig. 10c). CR8 treatment increased
the number of target quadrant entries in comparison to
the TBI + Veh +HB group indicating a reduction in
spatial memory deficits in the probe trial (p < 0.05 vs.
Veh + HB). Swim speeds did not differ across groups
(Fig. 10d; p = 0.4382).
Nonspatial memory was assessed using the novel ob-
ject recognition test on post-HB day 21 to evaluate if
CR8 treatment improves non-hippocampal-dependent
Fig. 3 Hypobaria exposure upregulates the expression of cyclin D1 in the ipsilateral cortex and hippocampus at 30 days after TBI. a Representative
immunofluorescent staining for cyclin D1 (red) and DAPI (blue). b, c Quantification of pixel intensity for cyclin D1 revealed significant increases in the TBI + HB
group in contrast to the TBI-alone tissue. A significant decrease of cyclin D1 expression was observed in the CR8 treatment group in comparison to the TBI/
Veh/HB group. N= 4 (sham), 6 (TBI), 6 (TBI/Veh/HB), 6 (TBI/CR8/HB). *p< 0.05, **p< 0.01, TBI vs. sham injury; $p< 0.05, TBI/Veh/HB vs. TBI; ##p< 0.01, TBI/CR8/HB
vs. TBI/Veh/HB. d Cyclin D1 (red) predominantly expressed by GFAP+ astrocytes (green; DAPI, blue). Scale bar=50 μm in a and d
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memory (Fig. 10e). Animals showed an equal preference
for the two identical objects during the training phase.
CR8 treatment significantly increased the discrimination
index in comparison to the TBI + vehicle + HB group in-
dicating an improvement in nonspatial memory (p < 0.01
vs. TBI + Veh +HB).
The forced swim test was performed on post-HB day
26 to determine if CR8 treatment reduces depressive-
like behaviors induced by TBI + HB (Fig. 10f ). CR8 treat-
ment did not significantly reduce the depressive-like be-
havior caused by TBI + HB (p > 0.05 TBI + Veh +HB vs.
TBI + CR8 +HB).
CR8 treatment reduced lesion volume induced by
hypobaria exposure following TBI
TBI-induced lesion volume was measured by unbiased ste-
reological techniques (Fig. 11). Histological assessment
showed that CR8 treatment (0.71 ± 0.17 mm3, n= 5) resulted
in a significant reduction in lesion size after injury as com-
pared with TBI +Veh +HB (2.8 ± 0.74 mm3; n = 5; P < 0.05).
Loss of hippocampal neurons and cell cycle inhibition
following TBI/HB
It is well known the TBI causes hippocampal neuronal
loss [7–15]. In our previous study, we have shown that
Fig. 4 Hypobaria exposure upregulates the expression of PCNA in the ipsilateral cortex and hippocampus at 30 days after TBI. a Representative
immunofluorescent staining for PCNA (green) and DAPI (blue). b, c Quantification of pixel intensity for PCNA revealed significant increases in the
TBI + Veh + HB group in contrast to the TBI-alone tissue. A significant decrease of cyclin D1 expression was observed in the CR8 treatment group in
comparison to the TBI/Veh/HB group. N = 4 (sham), 6 (TBI), 6 (TBI/Veh/HB), 6 (TBI/CR8/HB). *p < 0.05, TBI vs. sham injury; $$p < 0.01, TBI/Veh/HB vs. TBI;
#p < 0.05, ###p < 0.001, TBI/CR8/HB vs. TBI/Veh/HB. d Most of the PCNA+ cells (green) in the injured cortex were co-labeled with galectin 3-expressing
microglia/macrophages (red; DAPI, blue). Scale bar = 50 μm in a and 25 μm in d
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TBI + HB further increases hippocampal neuronal loss at
30 days in comparison to TBI alone [5]. Here, we evalu-
ated whether improvements in cognitive memory function
following CR8 treatment were associated with increased
hippocampal neuronal survival and total neuronal cell
numbers in the ipsilateral hippocampus at post-HB day 30
(Fig. 12). The CR8-treated TBI/HB group showed a sig-
nificant increase in the total number of surviving hippo-
campal neurons and number of surviving neurons in the
hippocampal DG region compared to the TBI + vehicle +
HB group (p < 0.05).
Discussion
Only two prior experimental studies have evaluated the
effects of hypobaria following rodent TBI. We recently
reported that hypobaria during simulated AE in a rat
TBI model, even with oxygen levels maintained in the
normal physiological range, worsens cognitive outcome
and increases progressive delayed neurodegeneration
and associated chronic inflammatory responses [5]. The
other study showed that hypobaric exposure increased
cytokine levels acutely after mouse TBI, but that group
did not control for the hypoxic effects of hypobaria [6].
The present study is the first to evaluate treatment to
limit the negative consequences of post-traumatic hypo-
baria in an animal model that simulates AE following
TBI. Treatment with the CDK inhibitor CR8 reduced
hypobaric-induced increases in CCA, post-traumatic
microglial activation, and neurodegeneration.
CCA in the brain has been well demonstrated experi-
mentally in models of TBI [11–15], spinal cord injury
[21, 24–29], stroke [30, 31], and Alzheimer’s disease
(AD) [32–35]; it has also been reported in clinical AD
[36, 37]. Both neurons and glial cells show increased ex-
pression after CNS injury, and such changes may persist
for weeks to months [8–10]. Chronic proliferation/
Fig. 5 Hypobaria exposure upregulates the expression of CDK4 in the ipsilateral cortex and hippocampus at 30 days after TBI. a Representative
immunofluorescent staining for CDK4 (green) and DAPI (blue). b, c Quantification of pixel intensity for CDK4 revealed significant increases in the
TBI + Veh + HB group in contrast to the TBI-alone tissue. A significant decrease of CDK4 expression was observed in the CR8 treatment group in
comparison to the TBI/Veh/HB group. N = 4 (sham), 6 (TBI), 6 (TBI/Veh/HB), 6 (TBI/CR8/HB). *p < 0.05, TBI vs. sham injury; $p < 0.05, TBI/CR8/HB vs. TBI;
#p < 0.05, ###p < 0.001, TBI/HB/CR8 vs. TBI/Veh/HB. d Some of the CDK4+ cells (green) in the injured cortex were co-labeled with NeuN-expressing
neurons (red; DAPI, blue). Scale bar = 50 μm in a and 25 μm in d
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activation of astrocytes and microglia resulting from
CCA may contribute to secondary injury and limit neu-
rorestoration [15, 18]. Reactive astrocytes are involved in
the formation of the glial scar, which can inhibit axonal
regeneration [38]. Activated microglia can produce pro-
inflammatory cytokines and ROS, leading to neuronal
degeneration [18]. Adult differentiated post-mitotic neu-
rons can re-enter the cell cycle; however, such re-entry
is associated with caspase-mediated neuronal apoptosis
[11, 39–41].
CCA is an intricate and highly regulated process
[8–10]. Through each phase in the cycle, there is a
systematic progression of synthesis and degradation of
phase-specific cyclin proteins. Cyclins bind and acti-
vate Ser/Thr kinases known as cyclin-dependent ki-
nases (CDKs), which in turn phosphorylate additional
Fig. 6 Cell cycle inhibition reduces protein expression of microglial/macrophages marker Iba-1 induced by hypobaria exposure after TBI. a Representative
immunoblots for Iba-1 and the loading control (GAPDH). b Quantification of the expression levels of Iba-1 protein revealed significant increases in the TBI +
Veh+HB group in contrast to the TBI-alone group in the ipsilateral cortex at day 1 after TBI. A significant decrease of Iba-1 expression was observed in the
CR8 treatment group in comparison to the TBI/Veh/HB group. N= 7 (sham), 9 (TBI), 10 (TBI//Veh/HB), 7 (TBI/CR8/HB). *p< 0.05, TBI vs. sham injury; ##p< 0.01,
TBI/Veh/HB vs. TBI no HB; $$p<0.01, TBI/CR8/HB vs. TBI/Veh/HB. c Representative immunofluorescent staining for Iba-1 (green) at 30 days post-injury and DAPI
(blue). d, e Quantification of Iba-1+ cells revealed significant increases in the TBI + Veh+HB group in contrast to the TBI-alone group. A significant decrease of
Iba-1+ cells was observed in the CR8 treatment group in comparison to the TBI/Veh/HB group. N= 4 (sham), 6 (TBI), 6 (TBI/Veh/HB), 6 (TBI/CR8/HB). *p< 0.05,
TBI vs. sham injury; $p< 0.05, $$p< 0.01, TBI/Veh/HB vs. TBI; ###p< 0.001, TBI/CR8/HB vs. TBI/Veh/HB. Scale bar= 50 μm
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Fig. 7 Microglial densities in the injured cortex were determined using unbiased stereological quantifications. CR8 treatment significantly reduced
the total number of microglia and the number of resting and activated microglia in comparison to the TBI + Veh + HB group. N = 6 (TBI/Veh/HB),
6 (TBI/HB/CR8). *p < 0.05, TBI/HB/CR8 vs. TBI/Veh/HB; **p < 0.01, TBI/HB/CR8 vs. TBI/Veh/HB
Fig. 8 Hypobaria exposure after TBI increases the expression of NADPH oxidase membrane component gp91phox. a Representative immunofluorescent
staining for gp91phox (red) and DAPI (blue) in the ipsilateral cortex and hippocampus at 30 days after TBI. b, c Quantification of gp91phox-positive cells revealed
significant increases in the TBI + Veh+HB group in contrast to the TBI-alone tissue. A significant decrease of gp91phox-positive cells was observed in the CR8
treatment group in comparison to the TBI/Veh/HB group. N= 4 (sham), 6 (TBI), 6 (TBI/Veh/HB), 6 (TBI/CR8/HB). *p< 0.05, TBI vs. sham injury; $$p< 0.01, TBI/
Veh/HB vs. TBI; ##p< 0.01, ###p< 0.001, TBI/CR8/HB vs. TBI/Veh/HB. d gp91phox-positive cells (red) in the injured cortex were co-labeled with Iba-1+ microglia/
macrophages (green; DAPI, blue). Scale bar= 50 μm in a and 25 μm in d
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substrates that promote transcription of other cyclins
and progression through the cycle. During the first
phase of the cell cycle, Gap 1 (G1), levels of cyclin D
increase. Cyclin D binds to CDK4, promoting phos-
phorylation of the retinoblastoma (Rb) family of pro-
teins. Phosphorylated Rb proteins dissociate from E2F
transcription factors, which translocate to the cell nu-
cleus and induce the transcription of other cyclins.
Proteins involved in the G1 phase of the cell cycle
have been identified as part of a pro-apoptotic path-
way in post-mitotic neurons [9, 10]. Activation of
CDK4 by cyclin D1 has been found to be necessary
for apoptosis in neurons that re-enter the cell cycle
[39, 41]. Furthermore, reduction of CDK4 expression
is protective against apoptosis in primary neuronal
cell cultures and ablation of the cyclin D1 gene limits
lesion development and improves functional outcomes
following TBI [42, 43].
Treatment with cell cycle inhibitors increases neuronal
survival and reduces glial proliferation/activation in
several CNS injury models, including rat and mouse TBI
models [11–15, 21, 25–29]. After fluid percussion injury,
administration of the pan-CDK inhibitor flavopiridol re-
duced cyclin D1 expression in neurons and glia in the
cortex and hippocampus; treatment also decreased
neuronal cell death, lesion volume, astroglial scar forma-
tion, and microglial activation and improved motor and
cognitive recovery [11]. Central administration of an-
other CDK inhibitor, roscovitine, 30 min after fluid
percussion-induced brain injury, significantly decreased
lesion volume, as well as improving motor and cognitive
recovery [12]. Roscovitine also attenuated neuronal
death and inhibited activation of CCA in neurons, as
well as decreasing microglial activation and astrogliosis.
In primary cortical microglial and neuronal cultures,
roscovitine treatment attenuated neuronal cell death and
decreased microglial activation as well as microglial-
dependent neurotoxicity [12]. Central administration of
CR8, a selective and highly potent CDK inhibitor struc-
turally related to roscovitine, attenuated CCA pathways,
and reduced post-traumatic apoptotic cell death at 24 h
post-TBI [14, 15]. Administration of CR8 at 3 h post-
injury limited CCA, reduced microglial activation and le-
sion volume, and improved behavioral outcomes in both
mouse and rat models of experimental TBI [14, 15].
In the present study, the cell cycle markers cyclin D1,
PCNA, and CDK4 were significantly increased following
TBI/HB at 24 h and 30 days compared to TBI alone. It
is well known that the upregulation of cell cycle proteins
occurs in both post-mitotic cells (neurons, mature
Fig. 9 Cell cycle inhibition reduces protein expression of astrocytes marker GFAP induced by hypobaria exposure following TBI. a Representative
immunofluorescent staining for GFAP (green) and DAPI (blue). b, c Quantification of GFAP+ cells revealed significant increases in the TBI + Veh +
HB group in contrast to the TBI-alone tissue. A significant decrease of GFAP+ cells was observed in the CR8 treatment group in comparison to
the TBI/HB group. N = 4 (sham), 6 (TBI), 6 (TBI/Veh/HB), 6 (TBI/CR8/HB). *p < 0.05, TBI vs. sham injury; $p < 0.05, TBI/Veh/HB vs. TBI; ###p < 0.001, TBI/
CR8/HB vs. TBI/Veh/HB. Scale bar = 50 μm
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oligodendroglia) and proliferating cell types including
microglia and astrocytes after TBI. In addition to neu-
rons, microglia, and astrocytes that are predominant cell
types in the brain, mature oligodendrocytes also undergo
apoptotic cell death at acute phase post-injury (e.g., d1,
d3 post-injury). We demonstrate changes across brain
cell types [11]. We have shown that CCA inhibitors
(flavopiridol, CR8) significantly decrease oligodendroglial
apoptosis in the injured spinal cord at 1 day post-injury
[24, 26]. Whether or not hypobaria (HB) in TBI animals
increases CCA expression in oligodendrocytes is intri-
guing, that merits further research. In addition, expres-
sion levels of the microglial/macrophage markers Iba-1
and gp91phox and the astroglial marker GFAP were sig-
nificantly higher in the TBI/HB group than in TBI ani-
mals without HB. Treatment with CR8 prior to HB
exposure significantly reduced the expression of cell
cycle, microglia/macrophage, and astrocytes markers in
comparison to the vehicle-treated TBI/HB group. CR8
significantly reduced deficits in spatial learning and
retention memory function caused by HB exposure plus
TBI, as reflected by the MWM and novel object recogni-
tion tests. However, CR8 treatment did not reduce
depressive-like behavioral changes associated with TBI +
HB exposure. Chronic microglial activation at 30 days
after TBI/HB was also attenuated by CR8 treatment.
There was no significant difference between TBI/HB/
CR8 and TBI-alone groups in any of the assays per-
formed. Although CR8 treatment at current dose and
timing of administration did not completely reverse
CDK4 signaling in the injured cortex (p < 0.05, TBI/HB/
CR8 vs. sham) at both acute and chronic time points
post-injury, the other CCA components tested (cyclin
D1, PCNA) as well as markers for inflammation (Iba-1,
gp91) and astrogliosis (GFAP) were significantly reduced
by CR8 treatment to close to a basal level. There was no
significant difference between TBI/HB/CR8 and sham
groups in the ipsilateral cortex and hippocampus at day
1 or days 28 post-injury. Thus, CR8-mediated reduction
of CCA and neuroinflammation are associated with
Fig. 10 Cell cycle inhibition by CR8 improves functional outcomes following TBI plus hypobaria. a–d Cognitive assessment of CR8 treatment using the
Morris water maze (MWM). The TBI + CR8 + HB group showed significant improvements in spatial learning deficits in comparison to the TBI + vehicle +
HB group following prolonged hypobaria exposure at 6 h after TBI. The swimming patterns during all trials on the fourth day of the acquisition phase
were analyzed to assess the search strategies utilized by the animals to locate the hidden platform. A chi-square analysis was used to compare strategies
between groups and was found to be significant (p < 0.0001, χ2 = 57.79, df = 4). Animals in the vehicle + HB group were less efficient in their search
strategy while attempting to locate the hidden platform. CR8 treatment increased the percentage of trials in which a spatial search strategy was utilized.
Spatial memory was assessed using the MWM probe trial on day 18 after HB by examining the number of entries into the target quadrant. CR8 treatment
increased the number of target quadrant entries in comparison to the TBI + Veh + HB group indicating a reduction in retention memory deficits in the
probe trial. Swim speeds did not differ across groups (p = 0.4382). e Nonspatial memory was assessed using the novel object recognition test on post-HB
day 21. Animals showed an equal preference for the two identical objects during the training phase. CR8 treatment significantly increased the
discrimination index in comparison to the TBI + Veh + HB group indicating an improvement in nonspatial memory. f Depressive-like behaviors
were assessed using the forced swim test. CR8 treatment did not significantly reduce the depressive-like behavior caused by TBI plus HB. N = 16 (sham),
14 (TBI + Veh + HB), 15 (TBI + CR8 + HB). *p < 0.05, **p < 0.01, TBI + CR8 + HB vs. TBI + Veh + HB
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TBI+HB TBI+HB+CR8a
b
Fig. 11 CR8 treatment reduces lesion volume induced by hypobaria exposure following TBI. Stereological assessment of lesion volume was performed at
30 days post-injury. a Representative images from each group are shown. Lesion cavities are marked by arrows. b There was a significant reduction in lesion
volume in the TBI + CR8+HB group when compared with the TBI + Veh+HB group. N= 5/group. *p< 0.05, TBI + CR8 +HB vs. TBI + Veh +HB
Fig. 12 Effect of CR8 treatment following TBI plus hypobaria on neuronal cell loss in the hippocampus. Total neuronal cell numbers in the
hippocampus ipsilateral to the site of injury were evaluated at 30 days post-injury. Unbiased stereological quantifications show that treatment with CR8
increased total neuronal density in the hippocampus and in the DG subregion compared with the TBI + Veh + HB group. N = 5 (TBI/Veh + HB),
5 (TBI/CR8/HB). * p < 0.05 TBI + CR8 + HB vs. TBI + Veh + HB
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improved functional outcome after HB exposure in TBI
animals. In the present study, CR8 dose and timing of ad-
ministration were based on previous studies using this
compound in experimental animal models of TBI—which
have shown neuroprotection by limiting microglial activa-
tion, astrocytosis, and neuronal loss. However, optimizing
CR8 treatment condition is intriguing which merits
further research. Collectively, these results suggest that
increases in CCA activation caused by HB exposure fol-
lowing TBI result in neuronal cell death and neurotoxic
microglial activation, which likely contribute to the
exacerbation of cognitive dysfunction. CR8 treatment at-
tenuated CCA and neuroinflammatory responses that
were intensified by HB exposure following TBI. Given that
changes in AE procedures and timing may not be possible
because of the need to rapidly transport critically ill pa-
tients to definitive treatment sites, use of cell cycle inhibi-
tors—previously examined in late human phase cancer
treatment studies—should be explored as a way of limiting
the negative consequences of AE in TBI patients.
Conclusions
Wartime casualties with traumatic brain injuries may be
exposed to prolonged periods of hypobaria during aero-
medical evacuation. As hypobaria exposure following
TBI has been shown to worsen pathophysiological and
cognitive outcomes, treatments to mitigate these effects
must be identified. This study evaluated the effects of
prolonged hypobaria in rats subjected to traumatic brain
injury on cell cycle and neuroinflammatory pathways
and examined the ability of the cell cycle inhibitor CR8
to alleviate the associated effects. Hypobaria exposure
following TBI significantly increased markers of cell
cycle activation and microglial activation. These changes
were limited by treatment with the cell cycle inhibitor
CR8 at 3 h post-injury. CR8 treatment also significantly
reduced cognitive deficits associated with hypobaria ex-
posure following injury.
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